| |
Anti-Fibrotic Activity of Oral, Dual CCR2 and CCR5 Antagonist Cenicriviroc in a Mouse Model of NASH and a Rat Model of TAA-Induced Liver Fibrosis
|
| |
| |
Reported by Jules Levin
HepDart Dec 9-12 2013, Hawaii
S.L. Friedman1, H. Chou1, T. Hashiguchi2, F. Hong1, H. Jenkins3, G.H.I. Wolfgang4, H. Yoneyama2, E. Lefebvre3
1Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, NY, USA, 2Stelic Institute & Co., Tokyo, Japan, 3Tobira Therapeutics, Inc., San Francisco, CA, USA, 4Kailua-Kona, HI, USA
|
|
| |
| |
|
|
|
